Peijia Medical (HKG:9996) has completed the first two implants with the TrilogyTM Transcatheter Heart Valve System to treat severe aortic regurgitation in Taiwan, China, a Wednesday filing with the Hong Kong bourse said.

The system is indicated for use in patients with symptomatic severe aortic regurgitation or symptomatic severe aortic stenosis who are at high risk for surgical aortic valve replacement.

Shares of the company were up over 8% in recent trade.